Publication: Impact of 13-Valent Pneumococcal Conjugate Vaccine on Colonization and Invasive Disease in Cambodian Children
Issued Date
2020-04-10
Resource Type
ISSN
15376591
Other identifier(s)
2-s2.0-85083541311
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol.70, No.8 (2020), 1580-1588
Suggested Citation
Paul Turner, Phana Leab, Sokeng Ly, Sena Sao, Thyl Miliya, James D. Heffelfinger, Nyambat Batmunkh, Fernanda C. Lessa, Jenny A. Walldorf, Terri B. Hyde, Vichit Ork, Md Shafiqul Hossain, Katherine A. Gould, Jason Hinds, Ben S. Cooper, Chanpheaktra Ngoun, Claudia Turner, Nicholas P.J. Day Impact of 13-Valent Pneumococcal Conjugate Vaccine on Colonization and Invasive Disease in Cambodian Children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Vol.70, No.8 (2020), 1580-1588. doi:10.1093/cid/ciz481 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/56259
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Impact of 13-Valent Pneumococcal Conjugate Vaccine on Colonization and Invasive Disease in Cambodian Children
Abstract
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. BACKGROUND: Cambodia introduced the 13-valent pneumococcal conjugate vaccine (PCV13) in January 2015 using a 3 + 0 dosing schedule and no catch-up campaign. We investigated the effects of this introduction on pneumococcal colonization and invasive disease in children aged <5 years. METHODS: There were 6 colonization surveys done between January 2014 and January 2018 in children attending the outpatient department of a nongovernmental pediatric hospital in Siem Reap. Nasopharyngeal swabs were analyzed by phenotypic and genotypic methods to detect pneumococcal serotypes and antimicrobial resistance. Invasive pneumococcal disease (IPD) data for January 2012-December 2018 were retrieved from hospital databases. Pre-PCV IPD data and pre-/post-PCV colonization data were modelled to estimate vaccine effectiveness (VE). RESULTS: Comparing 2014 with 2016-2018, and using adjusted prevalence ratios, VE estimates for colonization were 16.6% (95% confidence interval [CI] 10.6-21.8) for all pneumococci and 39.2% (95% CI 26.7-46.1) for vaccine serotype (VT) pneumococci. There was a 26.0% (95% CI 17.7-33.0) decrease in multidrug-resistant pneumococcal colonization. The IPD incidence was estimated to have declined by 26.4% (95% CI 14.4-35.8) by 2018, with a decrease of 36.3% (95% CI 23.8-46.9) for VT IPD and an increase of 101.4% (95% CI 62.0-145.4) for non-VT IPD. CONCLUSIONS: Following PCV13 introduction into the Cambodian immunization schedule, there have been declines in VT pneumococcal colonization and disease in children aged <5 years. Modelling of dominant serotype colonization data produced plausible VE estimates.